Amedisys Net Worth
Amedisys Net Worth Breakdown | AMED |
Amedisys Net Worth Analysis
Amedisys' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Amedisys' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Amedisys' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Amedisys' net worth analysis. One common approach is to calculate Amedisys' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Amedisys' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Amedisys' net worth. This approach calculates the present value of Amedisys' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Amedisys' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Amedisys' net worth. This involves comparing Amedisys' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Amedisys' net worth relative to its peers.
Enterprise Value |
|
To determine if Amedisys is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Amedisys' net worth research are outlined below:
| The company reported the previous year's revenue of 2.24 B. Net Loss for the year was (9.75 M) with profit before overhead, payroll, taxes, and interest of 1.01 B. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Amedisys, Inc. Shares Acquired by South Dakota Investment Council |
Amedisys Quarterly Good Will |
|
Amedisys uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Amedisys. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Amedisys' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Amedisys Target Price Consensus
Amedisys target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Amedisys' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Hold |
Most Amedisys analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Amedisys stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Amedisys, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAmedisys Target Price Projection
Amedisys' current and average target prices are 91.54 and 96.86, respectively. The current price of Amedisys is the price at which Amedisys is currently trading. On the other hand, Amedisys' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Amedisys Market Quote on 26th of February 2025
Target Price
Analyst Consensus On Amedisys Target Price
Know Amedisys' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Amedisys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amedisys backward and forwards among themselves. Amedisys' institutional investor refers to the entity that pools money to purchase Amedisys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Magnetar Financial Llc | 2024-12-31 | 637.4 K | Citadel Advisors Llc | 2024-09-30 | 604.3 K | Water Island Capital Llc | 2024-12-31 | 603.6 K | Geode Capital Management, Llc | 2024-12-31 | 573 K | Pacer Advisors, Inc. | 2024-12-31 | 558.2 K | Qube Research & Technologies | 2024-12-31 | 511.6 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 503.4 K | Calamos Advisors Llc | 2024-12-31 | 487.4 K | Cresset Asset Management, Llc | 2024-12-31 | 452.3 K | Vanguard Group Inc | 2024-12-31 | 3.2 M | Blackrock Inc | 2024-12-31 | 3.2 M |
Follow Amedisys' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3 B.Market Cap |
|
Project Amedisys' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | 0.09 | 0.09 | |
| Return On Equity | (0.01) | (0.01) |
When accessing Amedisys' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Amedisys' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Amedisys' profitability and make more informed investment decisions.
Please note, the presentation of Amedisys' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amedisys' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amedisys' management manipulating its earnings.
Evaluate Amedisys' management efficiency
Amedisys has return on total asset (ROA) of 0.0627 % which means that it generated a profit of $0.0627 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0721 %, meaning that it created $0.0721 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.09, whereas Return On Tangible Assets are projected to grow to (0.01). At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 18 M, whereas Net Tangible Assets are projected to grow to (288.1 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 31.02 | 32.57 | |
| Tangible Book Value Per Share | (8.05) | (7.65) | |
| Enterprise Value Over EBITDA | 18.29 | 23.95 | |
| Price Book Value Ratio | 2.61 | 2.57 | |
| Enterprise Value Multiple | 18.29 | 23.95 | |
| Price Fair Value | 2.61 | 2.57 | |
| Enterprise Value | 8.8 B | 9.2 B |
Amedisys benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 1.3871 | Revenue | Quarterly Revenue Growth 0.057 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amedisys insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amedisys' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amedisys insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amedisys Corporate Filings
F4 | 24th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 8th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 10th of December 2024 Other Reports | ViewVerify | |
F3 | 13th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Amedisys Earnings Estimation Breakdown
The calculation of Amedisys' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Amedisys is estimated to be 1.09765 with the future projection ranging from a low of 1.03 to a high of 1.1319. Please be aware that this consensus of annual earnings estimates for Amedisys is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.03 Lowest | Expected EPS | 1.13 Highest |
Amedisys Earnings Projection Consensus
Suppose the current estimates of Amedisys' value are higher than the current market price of the Amedisys stock. In this case, investors may conclude that Amedisys is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Amedisys' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 11 | 88.38% | 1.0 | 1.09765 | 2.52 |
Amedisys Earnings History
Earnings estimate consensus by Amedisys analysts from Wall Street is used by the market to judge Amedisys' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Amedisys' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Amedisys Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Amedisys' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Amedisys Earnings per Share Projection vs Actual
Actual Earning per Share of Amedisys refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Amedisys predict the company's earnings will be in the future. The higher the earnings per share of Amedisys, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Amedisys Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Amedisys, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Amedisys should always be considered in relation to other companies to make a more educated investment decision.Amedisys Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Amedisys' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | 1.17 | 1.0 | -0.17 | 14 | ||
2024-07-24 | 2024-06-30 | 1.19 | 1.32 | 0.13 | 10 | ||
2024-04-24 | 2024-03-31 | 1.02 | 1.03 | 0.01 | 0 | ||
2024-02-21 | 2023-12-31 | 1.03 | 0.94 | -0.09 | 8 | ||
2023-10-24 | 2023-09-30 | 1.08 | 0.98 | -0.1 | 9 | ||
2023-07-26 | 2023-06-30 | 1.09 | 1.37 | 0.28 | 25 | ||
2023-05-03 | 2023-03-31 | 0.88 | 1.0 | 0.12 | 13 | ||
2023-02-15 | 2022-12-31 | 1 | 1.16 | 0.16 | 16 | ||
2022-10-26 | 2022-09-30 | 1.22 | 1.15 | -0.07 | 5 | ||
2022-07-27 | 2022-06-30 | 1.23 | 1.47 | 0.24 | 19 | ||
2022-04-27 | 2022-03-31 | 1.12 | 1.23 | 0.11 | 9 | ||
2022-02-23 | 2021-12-31 | 1.18 | 1.18 | 0.0 | 0 | ||
2021-11-02 | 2021-09-30 | 1.37 | 1.53 | 0.16 | 11 | ||
2021-08-04 | 2021-06-30 | 1.66 | 1.69 | 0.03 | 1 | ||
2021-04-28 | 2021-03-31 | 1.43 | 1.54 | 0.11 | 7 | ||
2021-02-24 | 2020-12-31 | 1.47 | 1.49 | 0.02 | 1 | ||
2020-10-28 | 2020-09-30 | 1.27 | 2.24 | 0.97 | 76 | ||
2020-07-28 | 2020-06-30 | 0.81 | 1.34 | 0.53 | 65 | ||
2020-05-06 | 2020-03-31 | 0.97 | 1.05 | 0.08 | 8 | ||
2020-02-18 | 2019-12-31 | 0.93 | 0.94 | 0.01 | 1 | ||
2019-10-29 | 2019-09-30 | 0.9 | 1.15 | 0.25 | 27 | ||
2019-07-31 | 2019-06-30 | 0.99 | 1.21 | 0.22 | 22 | ||
2019-04-30 | 2019-03-31 | 0.9 | 1.11 | 0.21 | 23 | ||
2019-02-27 | 2018-12-31 | 0.85 | 0.91 | 0.06 | 7 | ||
2018-10-29 | 2018-09-30 | 0.77 | 0.95 | 0.18 | 23 | ||
2018-07-31 | 2018-06-30 | 0.78 | 1.0 | 0.22 | 28 | ||
2018-05-07 | 2018-03-31 | 0.67 | 0.79 | 0.12 | 17 | ||
2018-02-27 | 2017-12-31 | 0.58 | 0.56 | -0.02 | 3 | ||
2017-11-07 | 2017-09-30 | 0.54 | 0.56 | 0.02 | 3 | ||
2017-07-26 | 2017-06-30 | 0.5 | 0.62 | 0.12 | 24 | ||
2017-05-02 | 2017-03-31 | 0.41 | 0.47 | 0.06 | 14 | ||
2017-02-28 | 2016-12-31 | 0.39 | 0.44 | 0.05 | 12 | ||
2016-11-03 | 2016-09-30 | 0.42 | 0.36 | -0.06 | 14 | ||
2016-08-02 | 2016-06-30 | 0.42 | 0.42 | 0.0 | 0 | ||
2016-05-03 | 2016-03-31 | 0.33 | 0.33 | 0.0 | 0 | ||
2016-03-08 | 2015-12-31 | 0.35 | 0.4 | 0.05 | 14 | ||
2015-11-05 | 2015-09-30 | 0.33 | 0.34 | 0.01 | 3 | ||
2015-07-29 | 2015-06-30 | 0.33 | 0.43 | 0.1 | 30 | ||
2015-04-29 | 2015-03-31 | 0.2 | 0.3 | 0.1 | 50 | ||
2015-03-04 | 2014-12-31 | 0.26 | 0.27 | 0.01 | 3 | ||
2014-10-29 | 2014-09-30 | 0.15 | 0.28 | 0.13 | 86 | ||
2014-07-30 | 2014-06-30 | 0.04 | 0.25 | 0.21 | 525 | ||
2014-05-08 | 2014-03-31 | -0.04 | -0.07 | -0.03 | 75 | ||
2014-03-12 | 2013-12-31 | -0.01 | -0.05 | -0.04 | 400 | ||
2013-11-12 | 2013-09-30 | 0.13 | -0.01 | -0.14 | 107 | ||
2013-07-31 | 2013-06-30 | 0.1 | 0.17 | 0.07 | 70 | ||
2013-04-30 | 2013-03-31 | 0.18 | 0.13 | -0.05 | 27 | ||
2013-03-12 | 2012-12-31 | 0.22 | 0.23 | 0.01 | 4 | ||
2012-11-06 | 2012-09-30 | 0.27 | 0.33 | 0.06 | 22 | ||
2012-08-07 | 2012-06-30 | 0.24 | 0.27 | 0.03 | 12 | ||
2012-05-08 | 2012-03-31 | 0.22 | 0.22 | 0.0 | 0 | ||
2012-02-28 | 2011-12-31 | 0.28 | 0.49 | 0.21 | 75 | ||
2011-11-01 | 2011-09-30 | 0.5 | 0.36 | -0.14 | 28 | ||
2011-08-02 | 2011-06-30 | 0.68 | 0.67 | -0.01 | 1 | ||
2011-04-26 | 2011-03-31 | 0.65 | 0.62 | -0.03 | 4 | ||
2011-02-22 | 2010-12-31 | 0.91 | 0.95 | 0.04 | 4 | ||
2010-10-26 | 2010-09-30 | 0.91 | 0.89 | -0.02 | 2 | ||
2010-08-09 | 2010-06-30 | 1.15 | 1.16 | 0.01 | 0 | ||
2010-04-27 | 2010-03-31 | 1.28 | 1.29 | 0.01 | 0 | ||
2010-02-23 | 2009-12-31 | 1.31 | 1.35 | 0.04 | 3 | ||
2009-10-27 | 2009-09-30 | 1.27 | 1.29 | 0.02 | 1 | ||
2009-07-28 | 2009-06-30 | 1.02 | 1.27 | 0.25 | 24 | ||
2009-04-28 | 2009-03-31 | 0.97 | 0.99 | 0.02 | 2 | ||
2009-02-17 | 2008-12-31 | 0.91 | 0.98 | 0.07 | 7 | ||
2008-10-28 | 2008-09-30 | 0.82 | 0.89 | 0.07 | 8 | ||
2008-07-29 | 2008-06-30 | 0.69 | 0.82 | 0.13 | 18 | ||
2008-04-30 | 2008-03-31 | 0.58 | 0.62 | 0.04 | 6 | ||
2008-02-27 | 2007-12-31 | 0.6 | 0.63 | 0.03 | 5 | ||
2007-10-30 | 2007-09-30 | 0.56 | 0.61 | 0.05 | 8 | ||
2007-07-31 | 2007-06-30 | 0.53 | 0.57 | 0.04 | 7 | ||
2007-05-01 | 2007-03-31 | 0.5 | 0.51 | 0.01 | 2 | ||
2007-02-20 | 2006-12-31 | 0.49 | 0.48 | -0.01 | 2 | ||
2006-10-25 | 2006-09-30 | 0.45 | 0.48 | 0.03 | 6 | ||
2006-08-01 | 2006-06-30 | 0.39 | 0.41 | 0.02 | 5 | ||
2006-05-02 | 2006-03-31 | 0.35 | 0.34 | -0.01 | 2 | ||
2006-02-22 | 2005-12-31 | 0.41 | 0.34 | -0.07 | 17 | ||
2005-11-01 | 2005-09-30 | 0.37 | 0.39 | 0.02 | 5 | ||
2005-08-02 | 2005-06-30 | 0.33 | 0.38 | 0.05 | 15 | ||
2005-05-03 | 2005-03-31 | 0.3 | 0.34 | 0.04 | 13 | ||
2005-03-10 | 2004-12-31 | 0.27 | 0.29 | 0.02 | 7 | ||
2004-11-03 | 2004-09-30 | 0.27 | 0.29 | 0.02 | 7 | ||
2004-08-03 | 2004-06-30 | 0.24 | 0.29 | 0.05 | 20 | ||
2004-05-04 | 2004-03-31 | 0.21 | 0.26 | 0.05 | 23 | ||
2004-03-09 | 2003-12-31 | 0.17 | 0.23 | 0.06 | 35 | ||
2003-11-05 | 2003-09-30 | 0.13 | 0.17 | 0.04 | 30 | ||
2003-08-12 | 2003-06-30 | 0.09 | 0.12 | 0.03 | 33 | ||
2003-05-13 | 2003-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
2003-03-13 | 2002-12-31 | 0.08 | 0.08 | 0.0 | 0 | ||
2002-11-11 | 2002-09-30 | 0.08 | 0.1 | 0.02 | 25 | ||
2002-08-07 | 2002-06-30 | 0.16 | 0.13 | -0.03 | 18 |
Amedisys Corporate Management
| John Nugent | Chief Officer | Profile | |
| Pete Hartley | CTO Systems | Profile | |
| Kendra Kimmons | VP Relations | Profile | |
| Jennifer Griffin | Chief Secretary | Profile | |
| Janet Britt | VP Collections | Profile | |
| Francis Mayer | Senior Development | Profile |
Already Invested in Amedisys?
The danger of trading Amedisys is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amedisys is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amedisys. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amedisys is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.35) | Earnings Share 2.52 | Revenue Per Share | Quarterly Revenue Growth 0.057 | Return On Assets |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.